Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31904 in advanced solid tumors
NCT05461287Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS31904 in solid tumor (advanced stage), small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 24 months and 1 more. Status: unknown.
02
Drugs
QLS31904
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05461287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461287.